Neurogene Inc. Deferred Offering Costs
Neurogene Inc. (NGNE) had Deferred Offering Costs of $393.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-11
- 2026-06-30: Deferred Offering Costs $393.00K.
- 2026-03-31: Deferred Offering Costs $191.00K.
- 2025-12-31: Deferred Offering Costs $191.00K.
- 2025-09-30: Deferred Offering Costs $225.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-06-30 | $393.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $191.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $191.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $225.00K 10-Q · filed 2025-11-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-24 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2020-06-30 | $255.00K 10-Q · filed 2021-08-05 |
| 2015-06-30 | $87.00K 10-Q · filed 2015-08-06 |
| 2013-12-31 | $1.38M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |